Jpmorgan Chase & CO Affimed N.V. Transaction History

Jpmorgan Chase & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.32 - $0.62 $9,193 - $17,811	-28,729 Reduced 99.31%	199 $0
Q3 2023 Nov 14, 2023	BUY	$0.46 - $0.65 $10,614 - $14,998	23,074 Added 394.16%	28,928 $13,000
Q2 2023 Aug 11, 2023	SELL	$0.57 - $1.08 $61,965 - $117,407	-108,711 Reduced 94.89%	5,854 $3,000
Q1 2023 May 18, 2023	BUY	$0.66 - $1.29 $71,899 - $140,531	108,939 Added 1936.35%	114,565 $85,000
Q1 2023 May 11, 2023	SELL	$0.66 - $1.29 $55,783 - $109,030	-84,520 Reduced 93.76%	5,626 $4,000
Q4 2022 Feb 13, 2023	BUY	$1.1 - $2.45 $1,922 - $4,282	1,748 Added 1.98%	90,146 $111,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $9,850 - $16,686	5,026 Added 6.03%	88,398 $182,000
Q2 2022 Aug 11, 2022	BUY	$2.27 - $4.86 $32,862 - $70,358	14,477 Added 21.01%	83,372 $231,000
Q1 2022 May 11, 2022	BUY	$3.69 - $5.65 $49,077 - $75,145	13,300 Added 23.92%	68,895 $301,000
Q4 2021 Feb 10, 2022	BUY	$5.37 - $7.07 $22,457 - $29,566	4,182 Added 8.13%	55,595 $307,000
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $284,828 - $386,111	51,413 New	51,413 $317,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.